Discovery of Novel Triple A1/A2A/A2B Adenosine Receptor Antagonists for Cancer Immunotherapy

The A1, A2A, and A2B adenosine receptors are prime targets
for
immune cell activation and tumor suppression. Herein, we describe
the rationale design, synthesis, and biological evaluation of 6-aminonicotinonitrile
derivatives as triple A1/A2A/A2B adenosine receptor antagonists. Compound 14a demonstrated potent inhibitory activity (IC50 = 0.8 nM) of cAMP production in A2AR-HEK293 cells and strong binding
affinity (Ki = 0.6–21 nM) against
A1/A2A/A2B receptors. Compound 14a also effectively restored
T cell proliferation suppressed by 5′-N-ethylcarboxamidoadenosine
(NECA) and exhibited superior T cell-mediated cytotoxicity in coculture
systems with A1R- and PD-L1-expressed cancer cells compared with ciforadenant
(A2AR antagonist) and etrumadenant (A2AR/A2BR dual antagonist). Moreover,
the combination of compound 14a with avelumab, an anti-PD-L1
antibody, resulted in enhanced infiltration of effector T cells and
significantly increased the CD8+/Treg ratio in the CT26 syngeneic
mouse model, substantially inhibiting tumor growth. Therefore, compound 14a is a promising candidate for multitargeted immunomodulation
in cancer immunotherapy.